Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

Respiratory Research

Volumn 11, Issue , 2010, Pages

  VanDevanter, Donald R ^a   O'Riordan, Mary A ^a,b   Blumer, Jeffrey L ^a,b   Konstan, Michael W ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEFTAZIDIME PLUS TOBRAMYCIN; MEROPENEM; MEROPENEM PLUS TOBRAMYCIN; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; SPIROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; ACUTE DISEASE; COMPARATIVE STUDY; CYSTIC FIBROSIS; DISEASE COURSE; DRUG EFFECT; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957296044     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-137     Document Type: Article

References (15)

1. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry: 2008 Annual Data Report. 2009, Bethesda, MD: Cystic Fibrosis Foundation, Cystic Fibrosis Foundation.
2. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996, 335:179-88. Review, 10.1056/NEJM199607183350307, 8657217.
3. Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009, 44:989-96. 10.1002/ppul.21090, 19768806.
4. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006, 148:259-64. Review, 10.1016/j.jpeds.2005.10.019, 16492439.
5. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH. Return of FEV(1) after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010, 45:127-34. 10.1002/ppul.21117, 20054859.
6. Rabin HR, Butler SM, Wohl ME, Geller DE, Colin AA, Schidlow DV, Johnson CA, Konstan MW, Regelmann WE, . Epidemiologic Study of Cystic Fibrosis Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004, 37:400-6. 10.1002/ppul.20023, 15095322, Epidemiologic Study of Cystic Fibrosis.
7. Cystic Fibrosis Foundation Clinical practice guidelines for cystic fibrosis. 1997, Bethesda, MD: Cystic Fibrosis Foundation, Cystic Fibrosis Foundation.
8. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, . Clinical Practice Guidelines for Pulmonary Therapies Committee Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009, 180:802-8. 10.1164/rccm.200812-1845PP, 19729669, Clinical Practice Guidelines for Pulmonary Therapies Committee.
9. Wientzen R, Prestidge CB, Kramer RI, McCracken GH, Nelson JD. Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy. Am J Dis Child 1980, 134:1134-8.
10. Gold R, Carpenter S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1987, 111:907-13. 10.1016/S0022-3476(87)80217-2, 3316565.
11. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990, 141:914-21.
12. Fernandes BN, Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2008, (2):CD006682.
13. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005, 128:2336-46. 10.1378/chest.128.4.2336, 16236892.
14. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010,
15. Smith AL, Fiel S, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123:1495-1502. 10.1378/chest.123.5.1495, 12740266.